167 related articles for article (PubMed ID: 30978575)
1. PD-L1 expression by immunohistochemistry in salivary duct carcinoma.
Hamza A; Roberts D; Su S; Weber RS; Bell D; Ferrarotto R
Ann Diagn Pathol; 2019 Jun; 40():49-52. PubMed ID: 30978575
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of CD8-positive tumour-infiltrating lymphocytes and PD-L1 expression in salivary gland cancer.
Kesar N; Winkelmann R; Oppermann J; Ghanaati S; Martin D; Neumayer T; Balster S; Rödel C; Rödel F; von der Grün J; Balermpas P
Oral Oncol; 2020 Dec; 111():104931. PubMed ID: 32736208
[TBL] [Abstract][Full Text] [Related]
3. The expression of programed death ligand-1 could be related with unfavorable prognosis in salivary duct carcinoma.
Sato F; Akiba J; Kawahara A; Naito Y; Ono T; Takase Y; Murata K; Abe H; Yamaguchi T; Miyoshi H; Abe Y; Mihara Y; Tanikawa M; Akashi M; Kurose H; Umeno H; Yano H
J Oral Pathol Med; 2018 Aug; 47(7):683-690. PubMed ID: 29719073
[TBL] [Abstract][Full Text] [Related]
4. Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas.
Mukaigawa T; Hayashi R; Hashimoto K; Ugumori T; Hato N; Fujii S
J Surg Oncol; 2016 Jul; 114(1):36-43. PubMed ID: 27111278
[TBL] [Abstract][Full Text] [Related]
5. Real-world evidenceand clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors.
Song P; Zhang J; Shang C; Zhang L
Sci Rep; 2019 Mar; 9(1):4278. PubMed ID: 30862891
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
[TBL] [Abstract][Full Text] [Related]
7. Treatment Efficacy of PD-1 Inhibitor Therapy in Patients With Recurrent and/or Metastatic Salivary Gland Carcinoma.
Hashimoto K; Yasumatsu R; Kuga R; Hongo T; Yamamoto H; Matsuo M; Wakasaki T; Jiromaru R; Manako T; Toh S; Masuda M; Yamauchi M; Kuratomi Y; Uryu H; Nakashima T; Tamae A; Tanaka R; Taura M; Takeuchi T; Yoshida T; Nakagawa T
Anticancer Res; 2022 Feb; 42(2):981-989. PubMed ID: 35093898
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression in malignant salivary gland tumors.
Harada K; Ferdous T; Ueyama Y
BMC Cancer; 2018 Feb; 18(1):156. PubMed ID: 29409471
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma.
Yokoyama S; Miyoshi H; Nakashima K; Shimono J; Hashiguchi T; Mitsuoka M; Takamori S; Akagi Y; Ohshima K
Clin Cancer Res; 2016 Sep; 22(18):4727-34. PubMed ID: 27166394
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma.
Chen K; Cheng G; Zhang F; Zhang N; Li D; Jin J; Wu J; Ying L; Mao W; Su D
Oncotarget; 2016 May; 7(21):30772-80. PubMed ID: 27120796
[TBL] [Abstract][Full Text] [Related]
11. The immune microenvironment and expression of PD-L1, PD-1, PRAME and MHC I in salivary duct carcinoma.
Xu B; Jungbluth AA; Frosina D; Alzumaili B; Aleynick N; Slodkowska E; Higgins K; Ho A; Morris L; Ghossein R; Katabi N
Histopathology; 2019 Nov; 75(5):672-682. PubMed ID: 31237963
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas.
Nakano T; Takizawa K; Uezato A; Taguchi K; Toh S; Masuda M
Oral Oncol; 2019 Mar; 90():30-37. PubMed ID: 30846173
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors.
Cierna Z; Mego M; Miskovska V; Machalekova K; Chovanec M; Svetlovska D; Hainova K; Rejlekova K; Macak D; Spanik S; Ondrus D; Kajo K; Mardiak J; Babal P
Ann Oncol; 2016 Feb; 27(2):300-5. PubMed ID: 26598537
[TBL] [Abstract][Full Text] [Related]
14. [Current events in immunotherapy for upper aerodigestive tract cancer].
Outh-Gauer S; Le Tourneau C; Broudin C; Scotte F; Roussel H; Hans S; Mandavit M; Tartour E; Badoual C
Ann Pathol; 2017 Feb; 37(1):79-89. PubMed ID: 28111039
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value and clinicopathological roles of the tumor immune microenvironment in salivary duct carcinoma.
Hirai H; Nakaguro M; Tada Y; Saigusa N; Kawakita D; Honma Y; Kano S; Tsukahara K; Ozawa H; Okada T; Okami K; Yamazaki K; Sato Y; Urano M; Kajiwara M; Utsumi Y; Shimura T; Fushimi C; Shimizu A; Kondo T; Imanishi Y; Sakai A; Sato Y; Togashi T; Hanazawa T; Matsuki T; Yamazaki K; Nagao T
Virchows Arch; 2023 Sep; 483(3):367-379. PubMed ID: 37464232
[TBL] [Abstract][Full Text] [Related]
16. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
Gargano SM; Senarathne W; Feldman R; Florento E; Stafford P; Swensen J; Vranic S; Gatalica Z
Cancer Med; 2019 Dec; 8(17):7322-7329. PubMed ID: 31609094
[TBL] [Abstract][Full Text] [Related]
17. Prognostic markers in salivary gland cancer and their impact on survival.
Szewczyk M; Marszałek A; Sygut J; Golusiński P; Golusiński W
Head Neck; 2019 Sep; 41(9):3338-3347. PubMed ID: 31246357
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population.
Rong L; Liu Y; Hui Z; Zhao Z; Zhang Y; Wang B; Yuan Y; Li W; Guo L; Ying J; Song Y; Wang L; Zhou Z; Xue L; Lu N
Diagn Pathol; 2019 Jan; 14(1):6. PubMed ID: 30684971
[TBL] [Abstract][Full Text] [Related]
19. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.
Mocan T; Sparchez Z; Craciun R; Bora CN; Leucuta DC
Clin Transl Oncol; 2019 Jun; 21(6):702-712. PubMed ID: 30387047
[TBL] [Abstract][Full Text] [Related]
20. Correlation of PD-L1 Expression of Tumor Cells with Survival Outcomes after Radical Intensity-Modulated Radiation Therapy for Non-Metastatic Nasopharyngeal Carcinoma.
Lee VH; Lo AW; Leung CY; Shek WH; Kwong DL; Lam KO; Tong CC; Sze CK; Leung TW
PLoS One; 2016; 11(6):e0157969. PubMed ID: 27341634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
